Bill > SB306

This bill requires the Maryland State Workers' Compensation Commission to regulate reimbursement fees for prescription drugs and pharmaceutical services in workers' compensation claims, with implementation set for September 1, 2026. The bill specifies that reimbursement will be limited to an index or indexes based on the acquisition cost of drugs at the time of dispensing, which may include reasonable dispensing fees and other percentage adjustments determined by the Commission. Importantly, the bill does not prevent insurance carriers or employers from negotiating different reimbursement rates or using alternative pricing indexes through contracts with pharmacy benefits managers or pharmacy networks. Additionally, the bill mandates that the Maryland Prescription Drug Affordability Board conduct a comprehensive study on prescription drug affordability challenges in workers' compensation claims, examining prescribing and billing practices, investigating specific cost-related issues such as high-cost drug formulations and non-standardized billing practices, and requiring entities involved in workers' compensation prescription drug services to report necessary information. The board is required to submit its findings and recommendations to legislative committees by March 1, 2026, with the act taking effect on July 1, 2025.

Budget and Finance, Business and Industry

https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/SB0306?ys=2025RS